JP2024516001A - 敗血症の早期検出のためのｅｓｍ１マーカーパネル - Google Patents

敗血症の早期検出のためのｅｓｍ１マーカーパネル Download PDF

Info

Publication number
JP2024516001A
JP2024516001A JP2023566797A JP2023566797A JP2024516001A JP 2024516001 A JP2024516001 A JP 2024516001A JP 2023566797 A JP2023566797 A JP 2023566797A JP 2023566797 A JP2023566797 A JP 2023566797A JP 2024516001 A JP2024516001 A JP 2024516001A
Authority
JP
Japan
Prior art keywords
biomarker
subject
amount
assessing
biomarkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566797A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516001A5 (https=
Inventor
グリューネバルト，フェリックス
イェーガー，ヴィクトル・ヨハン・ラウル
クラマー，マルティン
シュッツ，フィリップ
ホルタイ，マリア フォン
ヴェーバー，シュテフェン
ベクマイヤー，ハイケ
ビーンヒューズ－テレン，ウルスラ－ヘンリケ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2024516001A publication Critical patent/JP2024516001A/ja
Publication of JP2024516001A5 publication Critical patent/JP2024516001A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/52—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving transaminase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/728—Bilirubin; including biliverdin
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4722—Proteoglycans, e.g. aggreccan
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91188—Transferases (2.) transferring nitrogenous groups (2.6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2023566797A 2021-04-30 2022-04-29 敗血症の早期検出のためのｅｓｍ１マーカーパネル Pending JP2024516001A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21171491.0 2021-04-30
EP21171491 2021-04-30
PCT/EP2022/061544 WO2022229416A2 (en) 2021-04-30 2022-04-29 Esm1 marker panels for early detection of sepsis

Publications (2)

Publication Number Publication Date
JP2024516001A true JP2024516001A (ja) 2024-04-11
JP2024516001A5 JP2024516001A5 (https=) 2025-05-12

Family

ID=75746433

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566797A Pending JP2024516001A (ja) 2021-04-30 2022-04-29 敗血症の早期検出のためのｅｓｍ１マーカーパネル

Country Status (5)

Country Link
US (1) US20240230676A1 (https=)
EP (1) EP4330679A2 (https=)
JP (1) JP2024516001A (https=)
CN (1) CN117597584A (https=)
WO (1) WO2022229416A2 (https=)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002039123A1 (fr) * 2000-11-09 2002-05-16 Institut Pasteur De Lille Trousse et procede de detection de la proteine esm-1
WO2007041623A2 (en) * 2005-10-03 2007-04-12 Biosite Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20140017707A1 (en) * 2011-01-21 2014-01-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and kits for predicting the risk of respiratory failure, renal failure or thrombopenia in a septic patient by measuring endocan levels in blood
US20160146838A1 (en) * 2014-11-20 2016-05-26 Jean Ronald Brisard System and method for ebola detection
WO2017060525A1 (en) * 2015-10-08 2017-04-13 Roche Diagnostics Gmbh Igfbp7 for prediction of risk of aki when measured prior to surgery
WO2018088455A1 (ja) * 2016-11-10 2018-05-17 国立大学法人千葉大学 敗血症診断薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2476597C (en) 2002-02-28 2011-05-17 Metanomics Gmbh & Co. Kgaa Mass spectrometry method for analysing mixtures of substances
US20090197794A1 (en) 2005-07-13 2009-08-06 Aird William C Methods of Diagnosing and Treating an Inflammatory Response
CN103123359B (zh) 2007-08-03 2015-07-29 B.R.A.H.M.S有限公司 降钙素原(pct)在患原发性非传染疾病的患者的风险分级和预后中的应用
RU2016112915A (ru) 2013-09-05 2017-10-09 Эф-Ай-Оу Корпорейшн Биомаркеры для раннего выявления критической или угрожающей жизни ответной реакции на заболевание и/или ответной реакции на лечение
GB201402293D0 (en) * 2014-02-11 2014-03-26 Secr Defence Biomarker signatures for the prediction of onset of sepsis

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002039123A1 (fr) * 2000-11-09 2002-05-16 Institut Pasteur De Lille Trousse et procede de detection de la proteine esm-1
JP2004522941A (ja) * 2000-11-09 2004-07-29 アンスティテュ パストゥール ドゥ リル タンパク質ｅｓｍ−１を検出するためのキット及び前記キットを使用する検出方法
WO2007041623A2 (en) * 2005-10-03 2007-04-12 Biosite Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
JP2009510478A (ja) * 2005-10-03 2009-03-12 バイオサイト インコーポレイテッド 全身性炎症反応症候群の診断および／または予後診断のための方法および組成物
US20140017707A1 (en) * 2011-01-21 2014-01-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and kits for predicting the risk of respiratory failure, renal failure or thrombopenia in a septic patient by measuring endocan levels in blood
JP2014503076A (ja) * 2011-01-21 2014-02-06 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 血液中のエンドカンレベルを測定することにより敗血症患者において呼吸不全、腎不全、又は血小板減少のリスクを予測するための方法及びキット
US20160146838A1 (en) * 2014-11-20 2016-05-26 Jean Ronald Brisard System and method for ebola detection
WO2017060525A1 (en) * 2015-10-08 2017-04-13 Roche Diagnostics Gmbh Igfbp7 for prediction of risk of aki when measured prior to surgery
JP2018532114A (ja) * 2015-10-08 2018-11-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 手術前に測定した際にａｋｉのリスクを予測するためのｉｇｆｂｐ７
WO2018088455A1 (ja) * 2016-11-10 2018-05-17 国立大学法人千葉大学 敗血症診断薬

Also Published As

Publication number Publication date
US20240230676A1 (en) 2024-07-11
WO2022229416A3 (en) 2023-02-23
CN117597584A (zh) 2024-02-23
EP4330679A2 (en) 2024-03-06
WO2022229416A2 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
JP2026048754A (ja) 敗血症の早期検出用のｐｃｔマーカーパネル
JP2024516680A (ja) 敗血症の早期検出用のｉｌ６マーカーパネル
JP2024516677A (ja) 敗血症の早期検出用のｎｇａｌマーカーパネル
JP2024516678A (ja) 敗血症の早期検出用のｓｔｒｅｍ１マーカーパネル
JP2024516001A (ja) 敗血症の早期検出のためのｅｓｍ１マーカーパネル
JP2024516679A (ja) 敗血症の早期検出用のｉｇｆｂｐ７マーカーパネル
JP2024515086A (ja) 敗血症の早期検出のためのｇｄｆ１５マーカーパネル
JP2024516681A (ja) 敗血症の早期検出のためのｓＦｌｔ１マーカーパネル
JP2024516665A (ja) 敗血症の早期検出のためのプレセプシンマーカーパネル
JP2024537774A (ja) 敗血症の早期検出のためのＭＲ－ｐｒｏＡＤＭマーカーパネル
JP2025506704A (ja) 敗血症を早期検出するためのｄｌｌ１マーカーパネル

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250430

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250430

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260304